Glucagon-like peptide-1 receptor agonists in patients with anthracycline related cardiac dysfunction
In cancer patients with anthracycline induced CTRCD, those treated with GLP-1RAs had significantly lower risk of adverse clinical outcomes.
Authors
- Milagros Pereyra (ORCID: https://orcid.org/0000-0003-4695-8436)
- Kwan Lee (ORCID: https://orcid.org/0000-0001-6302-9925)
- Hoang Nhat Pham (ORCID: https://orcid.org/0000-0001-8412-0082)
- Reza Arsanjani (ORCID: https://orcid.org/0000-0001-7081-4286)
- Isabel G. Scalia (ORCID: https://orcid.org/0000-0002-6459-9767)
- Mahmoud Hassan Abdelnabi (ORCID: https://orcid.org/0000-0001-8016-9049)
- Juan Farina (ORCID: https://orcid.org/0000-0002-5824-8485)
- Balaji Tamarappoo
- Chadi Ayoub (ORCID: https://orcid.org/0000-0001-5877-7478)
Institutions
- University of Arizona (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic Hospital (US)
Publication Details
- Journal
- Cardio-Oncology
- Published
- 2025-09-25
- DOI
- https://doi.org/10.1186/s40959-025-00381-y
- Citations
- 1
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 1.39